Effects of Genetic Variability on Rifampicin and Isoniazid Pharmacokinetics in South African Patients with Recurrent Tuberculosis

Pharmacogenomics - Tập 20 Số 4 - Trang 225-240 - 2019
Anushka Naidoo1, Maxwell Chirehwa2, Veron Ramsuran3,4, Helen McIlleron2, Kogieleum Naidoo5,6, Nonhlanhla Yende‐Zuma1, Ravesh Singh7, Sinaye Ngcapu1, John Adamson8, Katya Govender8, Paolo Denti2, Nesri Padayatchi5,6
1Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa
2Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa
3Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa KwaZulu-Natal Research Innovation & Sequencing Platform (KRISP), School of Laboratory Medicine & Medical Sciences, University of KwaZulu-Natal, Durban, South Africa
4KwaZulu-Natal Research Innovation & Sequencing Platform (KRISP), School of Laboratory Medicine & Medical Sciences, University of KwaZulu-Natal, Durban, South Africa
5Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa MRC-CAPRISA HIV-TB Pathogenesis & Treatment Research Unit, Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa
6MRC-CAPRISA HIV-TB Pathogenesis & Treatment Research Unit, Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa
7Department of Microbiology, National Health Laboratory Services, KZN Academic Complex, Inkosi Albert Luthuli Central Hospital, Durban, South Africa
8Pharmacology Core, Africa Health Research Institute (AHRI), Durban, South Africa

Tóm tắt

Từ khóa


Tài liệu tham khảo

WHO . Global Tuberculosis Report 2017 . http://www.who.int/tb/publications/global_report/en/

South African Department of Health. South African National Tuberculosis Management Guidelines . Pretoria : National Department of Health ( 2014 ). www.health-e.org.za/2014/06/10/guidelines-national-tuberculosis-management-guidelines/

10.1164/rccm.201407-1264OC

10.1016/S1473-3099(16)30274-2

10.1093/cid/cir184

10.1093/infdis/jir658

10.1086/599040

10.5588/ijtld.14.0405

10.1093/infdis/jit352

10.1093/cid/cix158

10.1007/s00228-006-0141-z

10.1128/AAC.01833-10

10.1111/j.1365-2125.2011.03940.x

10.1093/cid/cis353

10.1080/17512433.2017.1246179

10.1128/AAC.05526-11

10.3855/jidc.4696

10.2217/pgs-2017-0144

10.2147/PGPM.S15454

10.1046/j.1365-2362.33.s2.5.x

10.1111/j.1476-5381.2011.01724.x

10.1186/1476-0711-5-3

10.1097/FPC.0000000000000024

10.1093/nar/gkn1047

10.1097/FPC.0b013e3283385a1c

10.1210/er.2001-0038

10.1007/BF01086149

10.1007/s00228-012-1429-9

10.1128/AAC.00353-10

10.2147/DDDT.S87131

10.1371/journal.pone.0141002

10.1128/AAC.02599-12

10.1155/2014/108291

10.1086/598192

10.1093/jac/dkx004

10.1097/FPC.0000000000000062

10.1038/clpt.2012.96

10.1373/clinchem.2011.166306

10.2217/pgs.11.122

Beal S SheinerL BoeckmannAet al. NONMEM users guides (1989-2009) . MD USA ICON Development Solutions ( 2009 ).

10.1038/psp.2013.24

10.1007/s10928-007-9066-0

10.1023/A:1022972420004

Denti P , SmytheW , SimonssonUSet al. A population pharmacokinetic model for rifampicin auto-induction . Presented at:The 3rd International Workshop on Clinical Pharmacology of TB Drugs.Boston, MA, USA , 11 September 2010 .

Chirehwa MT , McIlleronH , RustomjeeRet al. Pharmacokinetics of pyrazinamide and optimal dosing regimens for drug-sensitive and -resistant tuberculosis . Antimicrob. Agents Chemother.61 ( 2017 ).

10.1023/A:1012299115260

10.1146/annurev.pharmtox.48.113006.094708

10.1371/journal.pmed.1002202

10.1093/bioinformatics/btv402

10.1002/cpt.180

10.1016/j.tube.2017.11.004

10.5588/ijtld.15.1007

10.1128/AAC.00210-17

10.1128/AAC.03931-14

Thông tin
Thông tin xuất bản

Pharmacogenomics

Tập 20 Số 4

225-240

Thông tin tác giả